vs
Side-by-side financial comparison of KRONOS WORLDWIDE INC (KRO) and Bio-Techne (TECH). Click either name above to swap in a different company.
KRONOS WORLDWIDE INC is the larger business by last-quarter revenue ($418.3M vs $295.9M, roughly 1.4× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs -19.8%, a 32.6% gap on every dollar of revenue. On growth, KRONOS WORLDWIDE INC posted the faster year-over-year revenue change (-1.1% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs -6.5%).
Kronos Incorporated was an American multinational workforce management and human capital management cloud provider headquartered in Lowell, Massachusetts, United States, which employed more than 6,000 people worldwide.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
KRO vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $418.3M | $295.9M |
| Net Profit | $-82.8M | $38.0M |
| Gross Margin | -0.9% | 64.6% |
| Operating Margin | -15.1% | 18.4% |
| Net Margin | -19.8% | 12.8% |
| Revenue YoY | -1.1% | -6.4% |
| Net Profit YoY | -527.3% | 68.3% |
| EPS (diluted) | $-0.72 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $418.3M | $295.9M | ||
| Q3 25 | $456.9M | — | ||
| Q2 25 | $494.4M | $317.0M | ||
| Q1 25 | $489.8M | $316.2M | ||
| Q4 24 | $423.1M | $297.0M | ||
| Q3 24 | $484.7M | $289.5M | ||
| Q2 24 | $500.5M | $306.1M | ||
| Q1 24 | $478.8M | $303.4M |
| Q4 25 | $-82.8M | $38.0M | ||
| Q3 25 | $-37.0M | — | ||
| Q2 25 | $-9.2M | $-17.7M | ||
| Q1 25 | $18.1M | $22.6M | ||
| Q4 24 | $-13.2M | $34.9M | ||
| Q3 24 | $71.8M | $33.6M | ||
| Q2 24 | $19.5M | $40.6M | ||
| Q1 24 | $8.1M | $49.1M |
| Q4 25 | -0.9% | 64.6% | ||
| Q3 25 | 10.3% | — | ||
| Q2 25 | 12.7% | 62.7% | ||
| Q1 25 | 21.8% | 67.9% | ||
| Q4 24 | 20.4% | 65.3% | ||
| Q3 24 | 20.9% | 63.2% | ||
| Q2 24 | 20.0% | 66.4% | ||
| Q1 24 | 14.9% | 67.4% |
| Q4 25 | -15.1% | 18.4% | ||
| Q3 25 | -4.2% | — | ||
| Q2 25 | 1.5% | -7.5% | ||
| Q1 25 | 7.8% | 12.2% | ||
| Q4 24 | 6.8% | 16.0% | ||
| Q3 24 | 8.0% | 13.8% | ||
| Q2 24 | 7.2% | 15.0% | ||
| Q1 24 | 4.1% | 22.1% |
| Q4 25 | -19.8% | 12.8% | ||
| Q3 25 | -8.1% | — | ||
| Q2 25 | -1.9% | -5.6% | ||
| Q1 25 | 3.7% | 7.1% | ||
| Q4 24 | -3.1% | 11.7% | ||
| Q3 24 | 14.8% | 11.6% | ||
| Q2 24 | 3.9% | 13.3% | ||
| Q1 24 | 1.7% | 16.2% |
| Q4 25 | $-0.72 | $0.24 | ||
| Q3 25 | $-0.32 | — | ||
| Q2 25 | $-0.08 | $-0.11 | ||
| Q1 25 | $0.16 | $0.14 | ||
| Q4 24 | $-0.11 | $0.22 | ||
| Q3 24 | $0.62 | $0.21 | ||
| Q2 24 | $0.17 | $0.26 | ||
| Q1 24 | $0.07 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $33.2M | $172.9M |
| Total DebtLower is stronger | $557.4M | $260.0M |
| Stockholders' EquityBook value | $751.1M | $2.0B |
| Total Assets | $1.8B | $2.5B |
| Debt / EquityLower = less leverage | 0.74× | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $33.2M | $172.9M | ||
| Q3 25 | $27.7M | — | ||
| Q2 25 | $18.9M | $162.2M | ||
| Q1 25 | $20.5M | $140.7M | ||
| Q4 24 | $106.7M | $177.5M | ||
| Q3 24 | $94.8M | $187.5M | ||
| Q2 24 | $133.8M | $152.9M | ||
| Q1 24 | $120.7M | $145.3M |
| Q4 25 | $557.4M | $260.0M | ||
| Q3 25 | $626.2M | — | ||
| Q2 25 | $589.3M | $346.0M | ||
| Q1 25 | $557.2M | $330.0M | ||
| Q4 24 | $507.4M | $300.0M | ||
| Q3 24 | $554.3M | $300.0M | ||
| Q2 24 | $423.7M | $319.0M | ||
| Q1 24 | $426.9M | $389.0M |
| Q4 25 | $751.1M | $2.0B | ||
| Q3 25 | $804.7M | — | ||
| Q2 25 | $846.8M | $1.9B | ||
| Q1 25 | $847.0M | $2.0B | ||
| Q4 24 | $817.0M | $2.1B | ||
| Q3 24 | $847.4M | $2.1B | ||
| Q2 24 | $774.6M | $2.1B | ||
| Q1 24 | $774.4M | $2.0B |
| Q4 25 | $1.8B | $2.5B | ||
| Q3 25 | $1.9B | — | ||
| Q2 25 | $1.9B | $2.6B | ||
| Q1 25 | $1.9B | $2.6B | ||
| Q4 24 | $1.9B | $2.7B | ||
| Q3 24 | $1.9B | $2.7B | ||
| Q2 24 | $1.7B | $2.7B | ||
| Q1 24 | $1.7B | $2.7B |
| Q4 25 | 0.74× | 0.13× | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.70× | 0.18× | ||
| Q1 25 | 0.66× | 0.16× | ||
| Q4 24 | 0.62× | 0.14× | ||
| Q3 24 | 0.65× | 0.14× | ||
| Q2 24 | 0.55× | 0.15× | ||
| Q1 24 | 0.55× | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $92.1M | — |
| Free Cash FlowOCF − Capex | $81.9M | — |
| FCF MarginFCF / Revenue | 19.6% | — |
| Capex IntensityCapex / Revenue | 2.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-40.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $92.1M | — | ||
| Q3 25 | $-7.9M | — | ||
| Q2 25 | $20.7M | $98.2M | ||
| Q1 25 | $-102.4M | $41.1M | ||
| Q4 24 | $49.3M | $84.3M | ||
| Q3 24 | $28.3M | $63.9M | ||
| Q2 24 | $38.2M | $75.5M | ||
| Q1 24 | $-43.3M | $81.0M |
| Q4 25 | $81.9M | — | ||
| Q3 25 | $-17.4M | — | ||
| Q2 25 | $9.5M | $93.3M | ||
| Q1 25 | $-114.4M | $31.0M | ||
| Q4 24 | $37.0M | $77.5M | ||
| Q3 24 | $19.2M | $54.7M | ||
| Q2 24 | $34.8M | $57.5M | ||
| Q1 24 | $-48.0M | $64.5M |
| Q4 25 | 19.6% | — | ||
| Q3 25 | -3.8% | — | ||
| Q2 25 | 1.9% | 29.4% | ||
| Q1 25 | -23.4% | 9.8% | ||
| Q4 24 | 8.7% | 26.1% | ||
| Q3 24 | 4.0% | 18.9% | ||
| Q2 24 | 7.0% | 18.8% | ||
| Q1 24 | -10.0% | 21.3% |
| Q4 25 | 2.4% | — | ||
| Q3 25 | 2.1% | — | ||
| Q2 25 | 2.3% | 1.5% | ||
| Q1 25 | 2.4% | 3.2% | ||
| Q4 24 | 2.9% | 2.3% | ||
| Q3 24 | 1.9% | 3.2% | ||
| Q2 24 | 0.7% | 5.9% | ||
| Q1 24 | 1.0% | 5.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -5.66× | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | 0.39× | 1.90× | ||
| Q2 24 | 1.96× | 1.86× | ||
| Q1 24 | -5.35× | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KRO
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
